37.25
+1.7(+4.78%)
Currency In USD
Address
9920 Pacific Heights Boulevard
San Diego, CA 92121
United States of America
Phone
858 704 4660
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
45
First IPO Date
October 08, 2018
| Name | Title | Pay | Year Born |
| Brian Lian | President, Chief Executive Officer & Director | 1.19M | 1966 |
| Michael Morneau | Vice President of Finance & Administration | 375,333 | 1965 |
| Gregory S. Zante | Chief Financial Officer | 713,000 | 1971 |
| Marianne Mancini | Chief Operating Officer | 735,000 | 1965 |
| Geoffrey E. Barker | Chief Development Officer | 0 | N/A |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.